Lowered cardiac sympathetic nerve performance in response to exercise in Parkinson's disease

Movement Disorders

Volumn 25, Issue 9, 2010, Pages 1183-1189

  Nakamura, Tomohiko ^a   Hirayama, Masaaki ^a   Yamashita, Fumitada ^a   Uchida, Kei ^a   Hama, Tetsuo ^a   Watanabe, Hirohisa ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac contractility; Cardiac sympathetic denervation; Exercise test; MIBG; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE;

ADULT; AGED; ARTICLE; BICYCLE ERGOMETER; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DENERVATION; DRUG UPTAKE; EXERCISE TEST; FEMALE; HEART MUSCLE CONTRACTILITY; HEART NERVE; HEART RATE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPATHETIC NERVE; AUTONOMIC NERVOUS SYSTEM DISEASES; BODY POSTURE; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC USE; ERGOMETRY; HEART; INNERVATION; KINESIOTHERAPY; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PHYSIOLOGY; PROCEDURES; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; AGED; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; ERGOMETRY; EXERCISE THERAPY; FEMALE; HEART; HEART RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PARKINSON DISEASE; POSTURE;

EID: 77955060285     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23127     Document Type: Article

References (39)

1. Hakusui S, Yasuda T, Yanagi T, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994;49:81-84.
2. Hamada K, Hirayama M, Watanabe H, et al. Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:423-426. (Pubitemid 36379361)
3. Satoh A, Serita T, Seto M, et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999;40: 371-375. (Pubitemid 29120107)
4. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60-67. (Pubitemid 28141060)
5. Orimo S, Ozawa E, Oka T, et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 2001;57:1140-1141.
6. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I- metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-194. (Pubitemid 29326950)
7. Cannon WB. A law of denervation. Am J Med Sci 1939;198: 737-750.
8. Nakamura T, Hirayama M, Ito H, et al. Dobutamine stress test unmasks cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 2007;263:133-138.
9. Imrich R, Eldadah BA, Bentho O, et al. Attenuated pre-ejection period response to tyramine in patients with cardiac sympathetic denervation. Ann N Y Acad Sci 2008;1148:486-489.
10. Imrich R, Eldadah BA, Bentho O, et al. Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. Parkinsonism Relat Disord 2009;15:122-127.
11. Osypka MJ, Bernstein DP. Electrophysiologic principles and theory of stroke volume determination by thoracic electrical bio-impedance. AACN Clin Issues 1999;10:385-399.
12. Rananei RN, Heywood JT, Elatre WA. Assessment of myocardial contractility and total arterial compliance by impedance cardiography determined parameters. Presented at the 6th Scientific Meeting of the Heart Failure Society of America, September 24, 2002.
13. (Abstract Published in the Journal of Cardiac Failure, 2002, Vol. 8, No. 4, Suppl pS-97.)
14. Springfield CL, Sebat F, Johnson D, Lengle S, Sebat C. Utility of impedance cardiography to determine cardiac vs. noncardiac cause of dyspnea in the emergency department. Congest Heart Fail 2004;10 (2 Suppl 2):14-16.
15. Parrott CW, Burnham KM, Quale C, Lewis DL. Comparison of changes in ejection fraction to changes in impedance cardiography cardiac index and systolic time ratio. Congest Heart Fail 2004;10 (2 Suppl 2):11-13.
16. Huntsman LL, Stewart DK, Barnes SR, Franklin SB, Colocousis JS, Hessel EA. Noninvasive Doppler determination of cardiac output in man. Clin Valid Circ 1983;67:593-602.
17. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of the idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
18. Nagamachi S, Wakamatsu H, Kiyohara S, et al. Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy. Ann Nucl Med 2008; 22:557-564.
19. Hanyu H, Shimizu S, Hirao K, et al. The role of 123I- metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord 2006;22:379-384.
20. Haensch CA, Lerch H, Jorg J, Isenmann S. Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson's disease. Parkinson Relat Disord 2009;15:134-137.
21. Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006;66:1850-1854. (Pubitemid 44049815)
22. Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997;133:353-358.
23. Fukuyama T. Basis of MIBG imaging. In: Yamamoto M, editor. Parkinson's disease: advances in pathology and autonomic nervous system (in Japanese). Tokyo: Chugai-Igakusha Co; 2004. p 72-83.
24. Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004;19:1370-1374. (Pubitemid 39534561)
25. Shibata M, Morita Y, Shimizu T, Takahashi K, Suzuki N. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 2009;276: 79-83.
26. Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 2006;12:284-288.
27. Sawada H, Oeda T, Yamamoto K, et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 2009;16:174-182.
28. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001;11:351-355. (Pubitemid 34461714)
29. Bengel FM, Ueberfuhr P, Schiepel N, Nekolla SG, Reichart B, Schwaiger M. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med 2001;345:731-738.
30. Isobe S, Izawa H, Takeichi Y, et al. Relationship between exercise- induced myocardial ischemia and reduced left ventricular distensibility in patients with nonobstructive hypertrophic cardiomyopathy. J Nucl Med 2003;44:1717-1724.
31. Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-766.
32. Shepherd RF, Shepherd JT. Control of blood pressure and the circulation in man. In: Banniser SR, Mathias CJ, editors. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system, Third ed. New York: Oxford University Press; 1993. p 78-93.
33. Werner WG, DiFrancisco-Donoghue J, Lamberg EM. Cardiovascular response to treadmill testing in Parkinson disease. J Neurol Phys Ther 2006;30:68-73.
34. Reuter I, Engelhardt M, Freiwaldt J, Baas H. Exercise test in Parkinson's disease. Clin Auton Res 1999;9:129-134.
35. Hunt S. Reinnervation of the transplanted heart: why is it important? N Engl J Med 2001;345:762-764.
36. Haapaniemi TH, Kallio MA, Korpelainen JT, et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. J Neurol 2000;247:868-874.
37. DiFrancisco-Donoghue J, Elokda A, Lamberg EM, Bono N, Werner WG. Norepinephrine and cardiovascular responses to maximal exercise in Parkinson's disease on and off medication. Mov Disord 2009;24:1773-1778.
38. Oka H, Mochio S, Onouchi K, Morita M, Yoshioka M, Inoue K. Cardiovascular dysautonomia in de novo Parkinson's disease. J Neurol Sci 2006;241:59-65. (Pubitemid 43112517)
39. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007;69:333-341. (Pubitemid 47205659)